Vaccine Conjugates Market Overview, Growth and Regional Outlook
Conjugate Vaccine are given to children to prevent transmission of diseases through infections and seasonal variation. Young children are more susceptible to infection that drives growth of the market. Moreover, increasing government support is expected to fuel the market’s growth during the forecast period. The International Conjugate Vaccine Market is expected to grow at a healthy CAGR of 10.5% during the forecast period 2018–2023.
Conjugate Vaccines are formed by covalently bonding a weak antigen to the strong antigen. This is done to boost the hosts’ immunological response. The poor antigen is a polysaccharide that is attached to the strong protein antigen. The major drivers for the growth of the global conjugate vaccine market are initiatives taken by the government, advancement in the vaccine formulation, and prevention of major infectious diseases, for instance meningitis and others.
An immature immune system can recognize these bacteria with the help of the conjugate vaccines, as these vaccines link the special polysaccharide coatings to an organism by producing immunity and response. The examples of conjugate vaccines are meningococcal vaccine to prevent meningitis, haemophilus influenzae type B (Hib) vaccine, and pneumococcal vaccine.
Get Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/4387
Some of the key players in this market are GlaxoSmithKline plc. Merck & Co., Inc. (U.S), Fablife. (India), SutroVax Inc.(U.S), Sanofi Pasteur SA.(France), Pfizer (U.S), Sinovac Biotech Ltd. (China), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(U.S).
On the regional basis, the market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. America dominates the largest market due to a significant use of the vaccine for preventing diseases and favorable conditions for research and development.
Europe is the second largest Conjugate Vaccines market in the globe followed by Asia Pacific. In Europe availability of funds for research and development activities and growing emphasis on research for prevention measures of diseases is increasing. Whereas, Asia Pacific shows the fastest growth in this market due to the increasing prevalence of communicable diseases. Developing countries in this region are emphasizing research on diseases caused to children’s and preventive measures for treating them. Mainly, India and China are expected to be an emerging and the fastest growing market due to the increasing population and prevalence of diseases.
The Middle East & Africa owns the lowest market in the global conjugate vaccines market due to less availability medical facilities.
The global Conjugate vaccine is segmented on the basis of type, indication, and end users. On the basis type it is segmented into Haemophilus B, monovalent, multivalent, others. On the basis of indication, it is segmented into Influenza, Pneumococcal, Meningococcal, others. On the basis of end users, it is segmented into pediatrics and adults.
Table Of Contents
1 Report Prologue
2 Market Introduction
3 Research Methodology
4 Market Dynamics
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Supply Chain Analysis
- Global Conjugates Vaccines Market, By Type
6.1 Haemophilus B
Browse Report Details at: https://www.marketresearchfuture.com/reports/conjugate-vaccine-market-4387
Browse Related Reports at:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.